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**The ASCOT Investigator Group**

*Study Principal Investigators* Joshua Davis, Justin Denholm, Steven Tong. *Trial Steering Committee* Asha Bowen (Chair), Megan Rees, David Paterson, David Price, Susan Morpeth, Matthew O'Sullivan, Jason Roberts, Thomas Snelling, Sue Anderson, Zoe McQuilton, Bala Venkatesh, Naomi Hammond, Vivekanend Jha. *Site principal investigators*. *Victoria* John Burston, James McMahon, Patrick Charles, Robert Commons, Daniel O'Brien, Andrew Mahoney, David Sheffield, Lyn-Li Lim, Brad Gardiner, Thomas Schulz, Joseph Torresi, Roy Chean, Joseph Sasadeusz, Ben Rogers, Craig Aboltins, Kasha Singh, Michelle Yong, David Lister, Kumar Visvanathan, James Molton, Alex Tai. *New South Wales* Rachel Chalmers, Marianne Martinello, Paul Wilson, Timothy Gray, Sarah Coghill, Hong Foo, Archana Sud, Jacob Williams, Nilar Lwin, Jeffrey Post, Sebastian van Haal, Richard Sullivan, Gail Matthews, Benjamin Chi Hin Kwan, Andrew Slack, Omar Shum, Belinda Cochrane, Ravindra Dotel, Timothy Gray, Timothy Gilbey, Michael Mina, Yuen Su, Chris Trethewy, Bernie Hudson, Arunavo Chatterji, Christaan Mostert. *West Australia* David New, Edward Raby, Sionh Hui, Owen Robinson, Julie Hart, Shu Jin Tan, Astrid Arellano, Jonathan Chambers. *Northern Territory* Jane Davis. *Queensland* Nastaran Rafiei, Simon Smith, Marjoree Sehu, Janath da Silva, Paul Griffin, Andrew Henderson, Khin Chaw, Keat Choong, Andrew Burke, Christopher Heather. *Australian Capital Territory* Sanjaya Senanayake. *South Australia* Mark Boyd, Emily Rowe, Mick Anagnostou. *Tasmania* Ali Trad, Alison Ratcliff. *New Zealand* Susan Morpeth, Jack Dummer, Hassan Bhally, Massimo Giola, Kate Grimwade, Catharina Li-Lin Chang, Ayesha Verrall, Stephen Hogg, Dalilah Restropo, Michael Maze, Stephen Ritchie. *ASCOT Biobank Steering Committee* Craig Gedye, Judy Chang, Michael Maze, Priyanka Pillai, Katie Flanagan. *Operational group* Jocelyn Mora, Jenny Post, Eileen Lam, Roberta Littleford, Naomi Knoblauch, Sandy Slow.

The ASCOT protocol was conceived and drafted by SYCT, JTD, JDa, and all authors were involved in review, amendments and approval of the final protocol. DP and TS had primary responsibility for statistical methodology. JR and DZ provided particular input in pharmacological dosing and safety considerations.

ASCOT has been initially funded in Australia by a variety of philanthropic donors, and in New Zealand by the Health Research Council, who have no role in study design, analysis and decision to publish.

Data recorded for this trial will be stored securely in a dedicated research database, accessible only to authorised investigators and study monitors. Findings will be submitted for presentation at appropriate conferences and for publication in peer-reviewed literature. Study updates will also be made available through the ASCOT website (<https://www.ascot-trial.edu.au/>). Investigators will actively pursue opportunities for data sharing, including individual participant meta-analysis.

This trial has been approved by the Melbourne Health Human Research Ethics Committee (HREC/62646/MH-2020), with initial approval given April 3, 2020. Additional ethics approvals have been given by Northern B Health and Disability Ethics Committee in New Zealand (20/NTB/75), Human Research Ethics Committee of the Northern Territory Department of Health and Menzies School of Health Research (HREC-2020-3713), Tasmania Health and Medical Human Research Ethics Committee (ref 21640), and the St John of God Health Care Human Research Ethics Committee (ref 1662). We certify that all appropriate ethical approval processes have been conducted as described above.

Informed consent to participate will be obtained prior to enrolment. Due to the stringent measures in infection control in hospitals, verbal consent will be obtained instead of written consent, with additional measures provided for stringent documentation and independent confirmation of consent to participate.
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